[Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus]. 1988

V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005907 Gliclazide An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion. Diabrezide,Diaglyk,Diaikron,Diamicron,Gen-Gliclazide,Gliklazid,Glyade,Glyclazide,Novo-Gliclazide,S-1702,S-852,Gen Gliclazide,Novo Gliclazide,S 1702,S 852,S1702,S852
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose

Related Publications

V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
June 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
January 2009, Mayo Clinic proceedings,
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
November 1999, Hospital practice (1995),
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
July 2018, BMJ (Clinical research ed.),
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
November 2003, The Annals of pharmacotherapy,
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
December 2022, Expert opinion on pharmacotherapy,
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
October 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
June 2022, Journal of diabetes and metabolic disorders,
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
March 2000, British journal of clinical pharmacology,
V Procacci, and A Giovine, and M G Roberto, and N Di Reda, and G Lasorsa, and G Vendemiale, and N Stufano, and E Altomare
November 2010, Pharmacogenomics,
Copied contents to your clipboard!